Dynamic Technology Lab Private Ltd Makes New $326,000 Investment in Vera Therapeutics, Inc. $VERA

Key Points

• Dynamic Technology Lab Private Ltd has made a new investment in Vera Therapeutics, purchasing 13,570 shares valued at approximately $326,000.
• Institutional investors currently own about 99.21% of Vera Therapeutics, with several hedge funds recently increasing their stakes in the company.
• Vera Therapeutics reported a quarterly earnings per share (EPS) of ($1.20), missing expectations, and equity analysts predict the company will post -$2.89 EPS for the current fiscal year.

Dynamic Technology Lab Private Ltd bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 13,570 shares of the company's stock, valued at approximately $326,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new position in Vera Therapeutics during the fourth quarter worth about $56,000. Quarry LP lifted its holdings in Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after acquiring an additional 500 shares in the last quarter. AlphaQuest LLC lifted its holdings in Vera Therapeutics by 404.7% during the first quarter. AlphaQuest LLC now owns 4,007 shares of the company's stock worth $96,000 after acquiring an additional 3,213 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Vera Therapeutics by 1,779.1% during the first quarter. GAMMA Investing LLC now owns 8,287 shares of the company's stock worth $199,000 after acquiring an additional 7,846 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Vera Therapeutics by 19.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company's stock worth $229,000 after acquiring an additional 1,572 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Stock Performance

VERA opened at $23.77 on Friday. The business's 50-day moving average price is $22.28 and its two-hundred day moving average price is $23.26. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -6.64 and a beta of 1.17. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same quarter in the previous year, the business earned ($0.62) earnings per share. Equities analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on VERA shares. Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. HC Wainwright reiterated a "buy" rating and set a $85.00 target price (up from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Wolfe Research reissued a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Finally, JPMorgan Chase & Co. dropped their price target on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $63.00.

Insider Activity

In related news, Director Patrick G. Enright bought 40,607 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were acquired at an average price of $22.35 per share, with a total value of $907,566.45. Following the completion of the transaction, the director owned 3,596,593 shares in the company, valued at $80,383,853.55. The trade was a 1.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 16.30% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.